Sector Overview
The Healthcare sector has seen steady filing activity over the past 12 months, with companies across the industry reporting on evolving market conditions and strategic initiatives. Annual 10-K filings from the sector's largest companies reveal a mix of operational improvements and forward-looking investments aimed at maintaining competitive positioning.
Quarterly 10-Q filings have highlighted ongoing adjustments to macroeconomic conditions, including interest rate sensitivity and supply chain dynamics. Several companies have disclosed material changes in their risk factors, reflecting the sector's adaptation to regulatory developments and shifting demand patterns.
Key Themes
- Companies adjusting strategies in response to macroeconomic conditions
- Increased disclosure around risk factors and regulatory compliance
- Capital allocation shifting toward long-term strategic investments
- Operational efficiency initiatives featuring in management discussions
Updated Jan 2025 · Based on filings from top Healthcare companies
Company Rankings
| # | Ticker | Company | Industry | Market Cap * | Filings |
|---|---|---|---|---|---|
| 1 | ABBV | AbbVie Inc. | Pharmaceutical Preparations | - | 272 |
| 2 | ABT | ABBOTT LABORATORIES | Pharmaceutical Preparations | - | 465 |
| 3 | AFL | AFLAC INC | Accident & Health Insurance | - | 431 |
| 4 | AMGN | AMGEN INC | Biological Products, (No Diagnostic Substances) | - | 545 |
| 5 | BDX | BECTON DICKINSON & CO | Surgical & Medical Instruments & Apparatus | - | 635 |
| 6 | BMY | BRISTOL MYERS SQUIBB CO | Pharmaceutical Preparations | - | 570 |
| 7 | BSX | BOSTON SCIENTIFIC CORP | Surgical & Medical Instruments & Apparatus | - | 603 |
| 8 | CAH | CARDINAL HEALTH INC | Wholesale-Drugs, Proprietaries & Druggists' Sundries | - | 551 |
| 9 | CI | Cigna Group | Hospital & Medical Service Plans | - | 176 |
| 10 | COR | Cencora, Inc. | Wholesale-Drugs, Proprietaries & Druggists' Sundries | - | 596 |
| 11 | CVS | CVS HEALTH Corp | Retail-Drug Stores and Proprietary Stores | - | 577 |
| 12 | ELV | Elevance Health, Inc. | Hospital & Medical Service Plans | - | 546 |
| 13 | GILD | GILEAD SCIENCES, INC. | Biological Products, (No Diagnostic Substances) | - | 483 |
| 14 | HCA | HCA Healthcare, Inc. | Services-General Medical & Surgical Hospitals, NEC | - | 677 |
| 15 | JNJ | JOHNSON & JOHNSON | Pharmaceutical Preparations | - | 512 |
| 16 | LLY | ELI LILLY & Co | Pharmaceutical Preparations | - | 420 |
| 17 | MCK | MCKESSON CORP | Wholesale-Drugs, Proprietaries & Druggists' Sundries | - | 563 |
| 18 | MDT | Medtronic plc | Electromedical & Electrotherapeutic Apparatus | - | 203 |
| 19 | MMM | 3M CO | Surgical & Medical Instruments & Apparatus | - | 618 |
| 20 | MRK | Merck & Co., Inc. | Pharmaceutical Preparations | - | 462 |
| 21 | ONC | BeOne Medicines Ltd. | Pharmaceutical Preparations | - | 348 |
| 22 | PFE | PFIZER INC | Pharmaceutical Preparations | - | 537 |
| 23 | REGN | REGENERON PHARMACEUTICALS, INC. | Pharmaceutical Preparations | - | 447 |
| 24 | SYK | STRYKER CORP | Surgical & Medical Instruments & Apparatus | - | 433 |
| 25 | UNH | UNITEDHEALTH GROUP INC | Hospital & Medical Service Plans | - | 661 |
Showing 1–25 of 27
Trending 8-K Filings
VERTEX PHARMACEUTICALS INC / MA 8-K Report, Material Agreement (Jul 7, 2026)
Vertex Pharmaceuticals Incorporated (VRTX) announced a definitive agreement to acquire Crinetics Pharmaceuticals, Inc. for $85.00 per share in cash, totaling a significant acquisition. This transaction is expected to close in the third quarter of 2026 and is not subject to a financing condition, providing clarity for investors on deal certainty. The acquisition aims to enhance Vertex's revenue growth and long-term earnings profile, with projections of exceeding $5 billion in annual revenue and becoming accretive to non-GAAP operating income in 2029. The deal terms include customary closing conditions such as stockholder approval from Crinetics and regulatory clearances. Vertex plans to finance the acquisition using a combination of cash on hand and a $4.5 billion unsecured bridge loan facility. This strategic move signals Vertex's intent to expand its market presence and pipeline, particularly in areas where Crinetics has promising assets like PALSONIFY and atumelnant.
REGENERON PHARMACEUTICALS, INC. 8-K Report, Financial Results (Jul 6, 2026)
Regeneron Pharmaceuticals, Inc. (REGN) has filed an 8-K report on July 6, 2026, providing a preliminary update on its expected financial results for the second quarter of 2026. The company anticipates a pre-tax acquired in-process research and development (IPR&D) charge of approximately $127 million. This charge is primarily related to up-front and opt-in payments made under various collaboration and licensing agreements. The estimated impact of this acquired IPR&D charge is a reduction of approximately $1.00 per diluted share on both Generally Accepted Accounting Principles (GAAP) and non-GAAP net income for the second quarter. Regeneron cautions that these are preliminary estimates and subject to change as financial closing procedures are completed, and actual results may differ. Investors should note that IPR&D charges are inherently unpredictable due to the uncertain nature of future collaborations and development milestones.
AbbVie Inc. 8-K Report, Financial Results (Jul 6, 2026)
AbbVie Inc. (ABBV) has filed an 8-K detailing preliminary second-quarter 2026 financial expectations, specifically addressing the impact of acquired In-Process Research and Development (IPR&D) and milestones expense. The company anticipates a pre-tax charge of $291 million related to these expenses, which is expected to negatively impact both GAAP and adjusted non-GAAP diluted earnings per share by $0.17 each. While these are preliminary estimates and subject to final financial closing procedures, investors should note this significant expense impacting near-term profitability. Despite the unfavorable impact from acquired IPR&D and milestones, AbbVie has reaffirmed its full-year 2026 adjusted diluted earnings per share guidance, now projected to be between $13.91 and $14.11. This revised guidance range incorporates the estimated second-quarter expense. The company also provided a specific second-quarter 2026 adjusted diluted earnings per share guidance range of $3.57 to $3.61, which also includes this expense. Investors are reminded that acquired IPR&D and milestones are inherently unpredictable and are not typically forecasted beyond the initial quarter they are incurred.
MCKESSON CORP 8-K Report, Executive Changes (Jul 1, 2026)
McKesson Corporation (MCK) has announced a significant executive transition, with Thomas L. Rodgers, Executive Vice President, Chief Strategy and Business Development Officer, intending to retire effective August 1, 2026. Mr. Rodgers has served as a key named executive officer, and his departure marks the end of his tenure with the company. The company has also taken proactive steps to ensure a smooth handover by appointing Ramesh Srinivasan to the newly titled position of Executive Vice President, Chief Strategy Officer, also effective August 1, 2026. This strategic appointment underscores McKesson's commitment to maintaining continuity and leadership in its strategic initiatives during this period of change.
AFLAC INC 8-K Report, Corporate Update (Jun 30, 2026)
Aflac Incorporated disclosed in an 8-K filing that its wholly owned subsidiary, Aflac Life Insurance Japan Ltd. ("Aflac Japan"), experienced a cybersecurity incident. An unauthorized third party accessed certain Aflac Japan systems between June 15 and June 25, 2026. While the investigation is ongoing, the compromised data includes policy details, personal information, and bank account information. Aflac Japan has taken steps to contain the breach and continues to serve its policyholders, though some systems were temporarily suspended. The incident is confined to Japan, and Aflac's U.S. operations were not affected. The full impact remains unknown, but potential risks include legal, reputational, and financial consequences, as well as regulatory inquiries and litigation.
BeOne Medicines Ltd. 8-K Report, Corporate Update (Jun 26, 2026)
BeOne Medicines Ltd. (ONC) announced the conclusion of a statutory tax audit in China. Through a settlement with the local tax authority, the Company has agreed to an income tax payment of approximately RMB 446 million, which includes surcharges and related interest. Importantly, this settlement did not involve any administrative penalties. This payment is anticipated to be recognized in the Company's U.S. GAAP financial statements for the second quarter of fiscal year 2026. This event is a follow-up to previously disclosed ongoing tax audits in various international jurisdictions, which carry the risk of materially different liabilities than currently estimated.
STRYKER CORP 8-K Report, Corporate Update (Jun 26, 2026)
Stryker Corporation (SYK) has filed a Form 8-K to provide updated segment reporting information. This filing details a change in organizational structure initiated in the first quarter of 2026, which combines the orthopaedic instruments portfolio from its Instruments business with the Mako and enabling technologies portfolio from its Other Orthopaedics business to form a new 'Ortho Tech' business. This strategic move aims to simplify the customer experience and accelerate market speed through focused innovation. While this reorganization creates a new internal business unit, Stryker will continue to report its financial results under its two existing reportable segments: MedSurg and Neurotechnology, and Orthopaedics. The primary purpose of this 8-K is to comply with SEC regulations requiring the recasting of prior period financial statements in certain future filings (like registration statements or proxy statements) to reflect these segment changes. Investors should note that this filing does not restate previously issued financial statements or update the Management's Discussion and Analysis from the 2025 10-K, but provides recast information for the year ended December 31, 2025, as detailed in Exhibit 99.1.
AbbVie Inc. 8-K Report, Regulation FD Disclosure (Jun 22, 2026)
AbbVie Inc. (ABBV) announced a significant strategic move via a joint press release with Apogee Therapeutics, Inc. on June 22, 2026, detailing a definitive agreement for AbbVie to acquire Apogee. This acquisition signals AbbVie's commitment to expanding its pipeline and therapeutic offerings. While specific financial terms of the deal are not disclosed in this 8-K, the accompanying investor presentation (Exhibit 99.2) likely elaborates on the strategic rationale and potential financial impact. Investors should note that this filing is primarily for Regulation FD disclosure, providing public access to the press release and presentation materials. The report highlights forward-looking statements concerning the benefits of the acquisition, integration plans, and the potential of Apogee's pipeline assets, including zumilokibart (APG777). However, the company also outlines numerous risks and uncertainties associated with the transaction, common in M&A activities, which could materially affect future results.
HCA Healthcare, Inc. 8-K Report, Executive Changes (Jun 18, 2026)
HCA Healthcare, Inc. has announced a significant leadership change with the upcoming departure of Dr. Michael Cuffe from his role as Executive Vice President and Chief Clinical Officer. This transition is effective August 31, 2026, after which Dr. Cuffe will remain with the company in a transitional capacity until February 2027. This move signifies a shift in the company's executive team, and investors will want to monitor the strategic implications and the appointment of a successor to this critical clinical leadership position.
PFIZER INC 8-K Report, Executive Changes (Jun 18, 2026)
Pfizer Inc. (PFE) has filed an 8-K report announcing a significant leadership change within its finance department. Effective August 15, 2026, Chief Financial Officer Dave Denton will step down to pursue an opportunity in the consumer goods sector. The company has emphasized that Mr. Denton's departure is voluntary and not due to any disagreements or concerns regarding Pfizer's financial performance, operations, or accounting practices. In light of Mr. Denton's departure, Pfizer has appointed Cecile Guegan, currently Senior Vice President of Finance, Global Biopharmaceutical Business, as Interim Chief Financial Officer, effective August 16, 2026. Ms. Guegan, a long-standing Pfizer employee since 2005 with extensive experience in various finance leadership roles within the company, will oversee the CFO responsibilities while a thorough search for a permanent successor is conducted. This transition is a key event for investors to monitor as it may impact financial strategy and investor relations.
Frequently Asked Questions
Updated Jan 2025 · Based on SEC filings from Healthcare companies